Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-06-30

Reporting Person: Manning Paul B (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	89709	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (1634515)		Indirect
Series B Preferred Stock	$		Common Stock (1315969)		Indirect
Series B Preferred Stock	$		Common Stock (657985)		Indirect

Footnotes

F1: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F2: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred and the Series B Preferred Stock
have no expiration date.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.